Big tech says AI can find a cure for cancer. So where is it?
THE SO WHAT
The gap between AI-for-healthcare narratives and bedside impact is still wide—data access, validation, and regulation are the bottlenecks, not model horsepower. If you’re building in health, orient around specific clinical workflows and trial pathways, not vague “cure cancer” promises.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechMore and more workers are feeling stressed at work due to security risks
If 91% of staff are stressed about security and 74% find recovery tools too hard to use, your incident response plan is a UX problem as much as a policy problem. Simplifying recovery workflows and training may buy you more real risk reduction than another detection SKU.
Deep & Emerging TechFinally, Smart Glasses With a Use Case That Isn’t Icky
FDA-cleared smart glasses that double as hearing aids anchor wearables in a clear medical use case instead of novelty AR. Expect more regulated, reimbursement-friendly hardware where the wedge is clinical value and the upside is ambient compute on the face.
Deep & Emerging TechApple's iOS 27 found to break NordVPN's scam and phishing protection — and it isn't the only privacy tool impacted
OS-level features like Connectivity Assist quietly breaking VPN-based scam and phishing protection is a reminder that platform updates are now a security dependency, not just a UX change. If you rely on third-party privacy tools, you need regression testing against major OS betas baked into your security operations.
Deep & Emerging TechVPN Deal of the Week: NymVPN drops low-commitment price plans – a cheaper way to try out its class-leading mixnet security
Cheaper, low-commitment access to mixnet-based VPNs lowers the barrier for users who want stronger metadata protection than standard VPN tunnels. If your threat model includes traffic analysis, it’s time to evaluate whether mixnet-style tools belong in your stack alongside or instead of traditional VPNs.